Lyell Immunopharma

Yahoo Finance • 3 months ago

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity InsiderNews Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a fundamental shift in how physi... Full story

Yahoo Finance • 4 months ago

Lyell's Ronde-cel Shows Durable Complete Responses With Manageable Safety In High-Risk LBCL

(RTTNews) - Lyell Immunopharma (LYEL) presented new clinical data from its ongoing Phase 1/2 trial of Ronde-cel in patients with relapsed or refractory large B-cell lymphoma in both the second-line and the third- or later-line settings at... Full story

Yahoo Finance • 4 months ago

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predo... Full story

Yahoo Finance • 5 months ago

Lyell Immunopharma buys exclusive global rights to colorectal cancer drug

[Cancer cells vis] koto_feja/E+ via Getty Images Lyell Immunopharma (LYEL [https://seekingalpha.com/symbol/LYEL]) announced its acquisition of exclusive global rights to LYL273, a CAR T-cell therapy aimed at treating metastatic colorectal... Full story

Yahoo Finance • 5 months ago

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S... Full story

Yahoo Finance • 5 months ago

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced... Full story

Yahoo Finance • 8 months ago

Lyell Immunopharma CEO Seely sells shares worth $8k

Lyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely sold a total of 797 shares of common stock on August 11 and 12, 2025. The sales, which covered tax withholding obligations from vested restricted stock units, amounted to $8,312... Full story

Yahoo Finance • 8 months ago

Lyell Immunopharma Inc (NASDAQ:LYEL) Reports Q2 2025 Earnings Beat with Clinical Progress on LYL314

LYELL IMMUNOPHARMA INC (NASDAQ:LYEL [https://www.chartmill.com/stock/quote/LYEL]) REPORTS Q2 2025 EARNINGS: NARROWER LOSS THAN EXPECTED, CLINICAL PROGRESS IN FOCUS Lyell Immunopharma Inc released its second-quarter 2025 financial results,... Full story

Yahoo Finance • 8 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACLE pivotal trial of LYL314 in patients w... Full story

Yahoo Finance • 8 months ago

Lyell Immunopharma registers 625,000 shares for resale

* Lyell Immunopharma (NASDAQ:LYEL [https://seekingalpha.com/symbol/LYEL]) registers 625,000 common shares for resale by selling stockholders. * Shares were issued as additional merger consideration under the October 2024 merger agreeme... Full story

Yahoo Finance • 9 months ago

Lyell Immunopharma to Participate in the H.C. Wainwright HCW@Home Series

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its... Full story

Yahoo Finance • 9 months ago

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its... Full story

Yahoo Finance • 9 months ago

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete r... Full story

Yahoo Finance • 10 months ago

Lyell Immunopharma strengthens clinical and commercial capabilities with executive appointments

* Lyell Immunopharma (NASDAQ:LYEL [https://seekingalpha.com/symbol/LYEL]) Monday announced [https://seekingalpha.com/pr/20130757-lyell-immunopharma-strengthens-clinical-and-commercial-capabilities-with-key-board-and] the appointment of M... Full story

Yahoo Finance • 10 months ago

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vic... Full story

Yahoo Finance • 11 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell lymphoma at the 18th In... Full story

Yahoo Finance • last year

Is Lyell Immunopharma, Inc. (LYEL) the Cheapest Stock Insiders Are Buying In March?

We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look at where Lyell Immunopharma, Inc. (NASDAQ:LYEL) stands against other cheapest stocks insiders are buying in March... Full story

Yahoo Finance • last year

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL)Presented positive i... Full story

Yahoo Finance • 2 years ago

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today an... Full story

Yahoo Finance • 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Extended funding of operations into 2027 by prioritizing investment in core clinical candidates and research platform value drivers as well as de-prioritizing selected early-stage research programsRemain on track to release initial clinica... Full story